- β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
Journal of medicinal chemistry (2013-04-18)
Hans Hilpert, Wolfgang Guba, Thomas J Woltering, Wolfgang Wostl, Emmanuel Pinard, Harald Mauser, Alexander V Mayweg, Mark Rogers-Evans, Roland Humm, Daniela Krummenacher, Thorsten Muser, Christian Schnider, Helmut Jacobsen, Laurence Ozmen, Alessandra Bergadano, David W Banner, Remo Hochstrasser, Andreas Kuglstatter, Pascale David-Pierson, Holger Fischer, Alessandra Polara, Robert Narquizian
PMID23590342
ZUSAMMENFASSUNG
An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of Aβ40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.
MATERIALIEN